The potential impact of comorbid neuropathology, such as cerebrovascular disease or AD-related pathology (amyloid-β and tau), must also be considered, the latter of which is known to be frequently present in DLB [152,153]. The gene discussed is MAPT; the disease is Lewy body dementia.